More Data From ESMO 2017

Get Permission

  • In GEICAM 2006-10, the addition of fulvestrant at 250 mg/d to anastrozole did not improve 5-year disease-free survival over anastrozole alone (91.0% vs 90.8%). 
  • “Immune induction” with chemotherapy or radiotherapy appeared to enhance response to nivolumab in women with metastatic triple-negative breast cancer.
  • A four-gene signature combining expression levels of genes associated with immune activation predicted the residual level of tumor-infiltrating lymphocytes after neoadjuvant chemotherapy for triple-negative breast cancer. High expression of this gene signature, compared to low expression, was associated with improved disease-free and overall survival. 
  • In metastatic triple-negative patients in the KEYNOTE-086 trial, the level of tumor-infiltrating lymphocytes was significantly associated with response to pembrolizumab, particularly in the first-line setting.
  • Neratinib, a dual inhibitor of HER2 and EGFR, significantly improved invasive disease–free survival in early-stage HER2-positive breast cancer previously treated with 1 year of trastuzumab, according to 5-year follow-up of the phase III ExteNET trial. The benefits were more robust in hormone receptor–positive patients.
  • Results of the phase III ICON8 trial reaffirmed that 3-weekly paclitaxel remains the standard of care for first-line therapy of ovarian cancer. Weekly dose-dense chemotherapy with paclitaxel was tolerable but did not improve progression-free survival compared with every-3-week paclitaxel (standard of care) in this setting. ■

Related Articles

International Trials Reveal New Findings in the Management of Breast and Ovarian Cancers

The European Society for Medical Oncology (ESMO) 2017 Congress, held in Madrid, featured important news including at least seven practice-changing or potentially practice-changing trials, which are covered in recent issues of The ASCO Post. Here we present additional highlights of studies in breast ...